PACS

PACS Group, Inc. 2026 Q1 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. PACS Group, Inc. is a leading post-acute healthcare company operating 323 skilled nursing, assisted living, and independent living facilities across 17 states. As of the reporting date, the company operated 32,757 skilled nursing beds and 2,759 assisted living beds. The company operates as a single reportable segment, focusing on acquiring underperforming facilities and transforming them into higher-acuity transitional care centers.

Key Financial Metrics

Note: Debt figures include line of credit, current maturities, and long-term debt net of deferred fees. Cash figures exclude restricted cash of $25.7 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 11.2% year-over-year, driven by a 9.9% increase in skilled nursing services revenue. This growth was supported by a 3.5% increase in patient days and improved occupancy rates (90.8% vs. 89.2%).
• Profitability Surge: Net income attributable to PACS Group, Inc. more than doubled, rising 184.2% to $80.7 million. Operating income increased 149.3% to $120.0 million.
• Expense Management: Cost of services rose 5.0%, primarily due to a 6.2% increase in salaries and wages. General and administrative expenses increased 13.8%, largely due to higher stock-based compensation ($8.1 million increase) and operational growth, partially offset by a decrease in legal fees related to prior investigations.
• Acquisitions: The company acquired three new facilities and one real estate property during the quarter, adding 234 assisted living beds. Cash used for facility acquisitions was $86.5 million.

Guidance, Outlook, Risks, and Contingencies

Outlook and Capital Allocation: Management believes current cash balances and operating cash flows are sufficient for the next 12 months. On May 7, 2026, the Board approved a $250 million share repurchase authorization. The company continues to pursue opportunistic acquisitions to expand its portfolio.

Material Weaknesses in Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to unremediated material weaknesses. These include deficiencies in the control environment and revenue recognition processes (specifically regarding new services and variable consideration). Remediation efforts are ongoing, including the hiring of a Chief Compliance Officer and enhanced training.

Legal and Regulatory Risks:

• DOJ Investigations: The company is cooperating with multiple ongoing Department of Justice investigations regarding potential False Claims Act violations, including allegations of improper patient referrals, billing practices under the Patient-Driven Payment Model (PDPM), and misuse of the 1135 COVID-19 waiver.
• SEC Investigation: The SEC is investigating the company's accounting, financial reporting, and internal controls.
• Securities Litigation: A consolidated securities class action (Manchin v. PACS Group, Inc.) and shareholder derivative actions allege a scheme to inflate revenue and profitability. Defendants have moved to dismiss the consolidated complaint.

Credit Facility Status: The company has a $600 million revolving credit facility. While currently in compliance, the company has entered into multiple forbearance agreements and amendments in 2025 and 2026 regarding technical events of default. A "Liquidity Requirement" covenant mandates maintaining at least $100 million in unrestricted cash until the delivery of Q2 2026 financial statements.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress of remediation plans for material weaknesses in revenue recognition and the control environment, as these remain unremediated.
• Regulatory Outcomes: Monitor the status of DOJ and SEC investigations, as unfavorable outcomes could result in significant fines, penalties, or restitution.
• Credit Covenant Compliance: Confirm continued compliance with the "Liquidity Requirement" ($100 million cash minimum) and other covenants under the Amended and Restated Credit Facility.
• Legal Exposure: Assess the potential financial impact of the consolidated securities class action and derivative lawsuits alleging revenue inflation.
• Operational Metrics: Track the "skilled mix" and occupancy rates of "New" vs. "Mature" facilities to validate the transformation strategy's effectiveness.